NASDAQ · PBH
Healthcare · Medical - Distribution
$49.20
Up+$0.80 (+1.65%)
Updated Oct 16, 2026, 4:35 AM
SID Score
5.8/10
Composite research score
Smart Money
58/100
Neutral
Price performance · PBH
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 15, 2026
PBH closed at $49.20 after 21 trading sessions, up 5.87% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | $49.41 | $50.84 | $48.83 | $49.20 | 533.93K |
| Oct 14, 2026 | $48.70 | $49.15 | $47.85 | $48.40 | 683.97K |
| Oct 13, 2026 | $49.52 | $49.78 | $48.45 | $48.50 | 494.72K |
| Oct 12, 2026 | $48.52 | $49.41 | $47.80 | $49.00 | 416.36K |
| Oct 9, 2026 | $47.80 | $48.73 | $47.48 | $48.23 | 323.71K |
| Oct 8, 2026 | $47.62 | $47.94 | $46.74 | $47.87 | 558.51K |
| Oct 7, 2026 | $46.57 | $47.72 | $46.34 | $47.57 | 460.85K |
| Oct 6, 2026 | $45.90 | $46.61 | $45.58 | $46.44 | 660.93K |
| Oct 5, 2026 | $45.11 | $45.875 | $44.77 | $45.60 | 604.39K |
| Oct 2, 2026 | $44.88 | $45.7486 | $44.60 | $45.26 | 543.3K |
| Oct 1, 2026 | $45.76 | $46.13 | $44.64 | $44.77 | 731.39K |
| Sep 30, 2026 | $46.69 | $46.69 | $45.85 | $45.87 | 583.49K |
| Sep 29, 2026 | $46.73 | $46.85 | $46.04 | $46.74 | 566.7K |
| Sep 28, 2026 | $46.25 | $47.33 | $46.2434 | $46.93 | 651.76K |
| Sep 25, 2026 | $45.34 | $46.72 | $44.97 | $46.61 | 467.65K |
| Sep 24, 2026 | $46.12 | $46.49 | $45.30 | $45.65 | 627.22K |
| Sep 23, 2026 | $47.45 | $47.455 | $45.91 | $45.92 | 503.99K |
| Sep 22, 2026 | $47.55 | $47.80 | $47.02 | $47.73 | 619.56K |
| Sep 21, 2026 | $45.01 | $47.00 | $44.46 | $46.80 | 660.42K |
| Sep 18, 2026 | $46.29 | $46.395 | $44.88 | $44.97 | 2.02M |
| Sep 17, 2026 | $47.20 | $47.485 | $45.90 | $46.47 | 504.03K |
The latest Smart Investors Daily articles mentioning PBH.
Company
Market Activity
Research & News
PBH research
Company profile and research snapshot.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 15, 2026 | Canaccord Genuity | Buy | — |
| May 14, 2026 | Oppenheimer | Perform | — |
| May 7, 2026 | Oppenheimer | Outperform | — |
| Feb 2, 2026 | Jefferies | Hold | — |
| Nov 7, 2025 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 7, 2026
Prestige Consumer (NYSE:PBH) reported first-quarter financial results on Thursday. The transcript from the company's first-quarter earnings call has been provided below. This transcript is brought to you by Benzinga
Yahoo · Oct 1, 2026
BP and PBH made it to the Zacks Rank #1 (Strong Buy) value stocks list on October 1, 2026.
Yahoo · Sep 30, 2026
PBH vs. NEOG: Which Stock Is the Better Value Option?
Yahoo · Sep 30, 2026
Women may be talking more openly about intimate health and wellness, but that does not necessarily mean the discomfort has disappeared. New research from Summer's Eve® finds that while nearly two-thirds of U.S. women (63%) believe women today are more comfortable openly discussing intimate health and wellness than they were five years ago, more than half (52%) have personally avoided talking to someone about an intimate health and wellness concern because they felt embarrassed or uncomfortable.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PBH.
